Overview

Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

Status:
Completed

Trial end date:
2021-06-09

Target enrollment:

Participant gender:

Summary

The study is intended to assess the effect on glycaemic control of AZD9567, as measured by the glucose AUC(0-4) versus baseline following a standardised mixed meal tolerance test (MMTT), compared to prednisolone in adults with type 2 diabetes mellitus (T2DM). The study will also evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD9567.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Prednisolone